Wockhardt Limited , a global pharmaceutical company, has reported its financial results for the quarter ended June 30, revealing a mixed performance across standalone and consolidated figures.

Standalone Performance

On a standalone basis, Wockhardt demonstrated strong growth:

Consolidated Results

However, the consolidated results painted a different picture:

Exceptional Item and US Market Exit

A significant development impacting Wockhardt's financial results was the decision to exit the US generic pharmaceutical segment:

• The company filed for voluntary liquidation under Chapter 7 of the US Bankruptcy Code for its US subsidiaries, Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC, on July 11.
• As a result, Wockhardt recorded an exceptional item charge of ₹97.00 crore, representing the impairment of goodwill related to its US operations.

Business Segment and Global Presence

• Wockhardt continues to operate exclusively in the pharmaceutical business segment.
• The company maintains a global presence with 28 subsidiaries worldwide.

Outlook

Wockhardt's decision to exit the US generic pharmaceutical market marks a significant shift in its global strategy. The strong standalone performance, coupled with the challenges reflected in the consolidated results, suggests a period of transition for the company. The focus will likely be on how Wockhardt navigates this strategic pivot and leverages its global subsidiaries to drive future growth.

Note: All figures are based on the latest available financial results unless otherwise specified.

Wockhardt Limited has announced a significant breakthrough in the treatment of drug-resistant infections, as reported in a leading U.K. medical journal. The company's novel antibiotic, Zaynich® (Zidebactam/Cefepime, WCK 5222), has successfully treated a severe pan-drug resistant infection in a U.S. liver transplant patient, demonstrating its effectiveness against challenging antibiotic-resistant infections in critical patient populations.

Case Study Details

The complex case, published in the Journal of Antimicrobial Chemotherapy – AMR, details the successful use of Zaynich® in treating a critically ill U.S. liver transplant patient. The patient was suffering from a pan-drug resistant infection, which was resistant to all available antibiotics in the United States.

Challenging Infection

The case report, jointly authored by clinicians from Houston Methodist Hospital, Weill Cornell Medical College, and Johns Hopkins, revealed that the patient was infected with two different pathogens – Pseudomonas and Klebsiella. Both pathogens were resistant to recently introduced antibiotics such as cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam, and imipenem/relebactam. Genetic analysis showed that each pathogen harbored four distinct resistance mechanisms, leading to pan-drug resistance.

Treatment and Results

After an unsuccessful 10-week treatment with cefiderocol and eravacycline, the patient's condition worsened, with persistent fever, chills, and new liver abscesses. Facing a high risk of transplant failure, a multidisciplinary team sought emergency access to Zaynich®.

The results were remarkable:

• Zaynich® was administered for 14 days around the time of the liver transplant.
• Within 11 days, the patient showed significant clinical improvement.
• The patient was transferred from ICU to a regular floor.
• Follow-up imaging showed no signs of active infection.
• The patient remained infection-free even six weeks after completing treatment.
• The liver transplant was successful, allowing doctors to safely resume chemotherapy for the underlying cancer.

About Zaynich®

Zaynich® is a novel, proprietary antibiotic developed by Wockhardt, combining Zidebactam and Cefepime to combat multi-drug resistant Gram-negative infections. Key points about Zaynich® include:

• Recently completed a global, pivotal Phase III clinical trial.
• Successfully conducted multiple Phase I clinical pharmacology studies in the United States.
• Completed a multi-indication clinical study in India, targeting carbapenem-resistant infections.
• Treated over 50 patients in India and the U.S. with highly resistant infections under compassionate use programs.

Wockhardt's Commitment to Antibiotic Innovation

Wockhardt has been at the forefront of antibiotic innovation for over 27 years, focusing on combating multi-drug resistant infections. The company's efforts have resulted in:

• A strong pipeline of six antibiotics at various stages of clinical development and commercialization.
• All six antibiotics granted Qualified Infectious Disease Product (QIDP) designation by the U.S. FDA.
• Three novel antibiotics already approved for clinical use.
• Two more antibiotics in the final stages of development.

This latest success with Zaynich® further solidifies Wockhardt's position as a leader in developing effective treatments for challenging antibiotic-resistant infections, addressing a critical need in global healthcare.